Reversible cardiomyopathy due to chronic use of xylometazoline topical nasal spray

Decisive Bearing of Organizational Dynamics on the Application and Success of Hospital-Based Cardiac Rehabilitation

“…Discussion. Although previous reports have revealed that topical nasal decongestant abuse can cause severe systemic effects such as ischemic stroke, 1 hypertension, 2 and reversible cardiomyopathy, 3 to my knowledge, these patients are the first reported cases indicating that nasal decongestant use can cause atrial fibrillation. Tramazoline is an imidazoline derivative that binds to peripheral a-adrenergic and imidazoline receptors and thereby increases arterial pressure and causes complex neuroendocrine reactions.…”

“…1,2 Cardiac rehabilitation is a comprehensive secondary prevention program involving exercise training as well as medical evaluation, cardiac risk factor modification, education, and counseling. 1 It been established as one of 9 performance measures for patients with ischemic heart disease by the American College of Cardiology Foundation and other preeminent medical organizations, 3 and it has growing relevance amid present-day surges of obesity, sedentariness, multimorbidity, aging, and other complexities of care for a growing spectrum of patients. 1,4 Yet, CR underutilization remains entrenched.…”

Effect of withdrawal of fusafungine from the market on prescribing of antibiotics and other alternative treatments in Germany: a pharmacovigilance impact study

“…The most common other N&Ts in fusafungine-prescribing practices during the study period included mometasone (21.6%), xylometazoline (14.2%), xylometazoline in combination with dexpanthenol (10.1%) and multisubstance preparations (9.7%). These substances may carry their own risks, for example xylometazoline could cause sympathomimetic adverse reactions [17][18][19][20], and mometasone could cause adrenal suppression if significant systemic absorption occurs when used in high doses over long periods of time [21][22][23]. Long-term use of nasal decongestants such as xylometazoline is also associated with a risk of development of rhinitis medicamentosa [24].…”